Research Article
Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials
Figure 8
Meta-regression graph describing the effect of the prevalence of glycoprotein IIb/IIIa inhibitors use on the risk difference for mortality according to vascular access (radial or femoral).